Lundbeck says Longboard Pharmaceuticals’ drug, bexicaserin, has potential applications in a range of rare epilepsies. Last month, the biotech began a Phase 3 clinical trial testing the drug in Dravet syndrome.
Takeda Pharmaceutical’s soticlestat did not meet Phase 3 goals in Dravet syndrome and Lennox-Gastaut syndrome, two rare forms of epilepsy. But the pharma giant points to results on secondary goals and subgroup analyses, and plans to discuss with regulators the “totality of data.”
CEO and neuroscientist Dr. Iftach Dolev on how the new device can bring a powerful tool to psychiatrists and neurologists alike.
The European Commission approved GW Pharma's Epidyolex as a treatment for seizures in two rare and severe forms of epilepsy. The drug won FDA approval last year.
The FDA approved the cannabis-based drug for treating seizures in two severe forms of epilepsy.